Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
Clinical trial NCT03734198 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03734198
- Sponsor
- French Innovative Leukemia Organisation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-19
- Primary completion
- 2023-06-17
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.